Amphiphilic Or Oligomer Modified Peptide (e.g., Magainin, Peptide Nucleic Acid, Or Pegylated Peptide, Etc.) Utilizing Patents (Class 514/3.2)
-
Patent number: 11286489Abstract: The present invention is directed to a composition that includes an amphiphile, its use in a method of preventing and/or treating cancer, and its use in a method of producing a pharmaceutical composition. In certain embodiments, the amphiphile includes a hydrophilic peptide that binds to a Plenty of SH3 domain (POSH) and inhibits or disrupts a POSH scaffold network, a hydrophobic moiety, and an aptamer. The present invention is also directed to other POSH inhibitor complex biomolecules that do not contain a hydrophobic moiety.Type: GrantFiled: February 13, 2017Date of Patent: March 29, 2022Assignee: THE CURATORS OF THE UNIVERSITY OF MISSOURIInventors: Mark Daniels, Bret Ulery, David Porciani, Kwaku Tawiah, Josiah Smith, Leah Cardwell, Donald Burke, Erin Newcomer
-
Publication number: 20150148286Abstract: Provided are compositions and methods for potentiating the effect of antibiotics. The compositions comprise a non-covalent complex of alpha-lactalbumin and fatty acid. The fatty acids are cis, unsaturated, C14 to C20 fatty acids. The complex and antibiotic can be administered to an individual together or separately. The antibiotic may be one to which resistance has developed.Type: ApplicationFiled: July 5, 2013Publication date: May 28, 2015Inventors: Anders P. Hakansson, Laura R. Marks, Hazeline Hakansson
-
Patent number: 9040478Abstract: The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.Type: GrantFiled: October 5, 2012Date of Patent: May 26, 2015Assignee: Lipoxen Technologies LimitedInventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis
-
Publication number: 20150141324Abstract: It is provided furin inhibitors and their uses for treating pathogen infection. Particularly, it is provided a method or use for the treatment of a pathogen infection, in a subject, comprising administering to the subject a therapeutically effective amount of the furin inhibitors or the composition disclosed, thereby preventing or treating pathogen infection, in the subject.Type: ApplicationFiled: August 31, 2012Publication date: May 21, 2015Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.Inventors: Robert Day, Witold A. Neugebauer, Yves Dory
-
Publication number: 20150080289Abstract: Disclosed are amphiphilic peptides. Also disclosed are methods of treating proliferative disease, bacterial infection, viral infection and fungal infection, endotoxin neutralization and a method of removing biofilm. Also disclosed is the use of the amphiphilic peptides.Type: ApplicationFiled: August 29, 2013Publication date: March 19, 2015Inventors: Yi-Yan Yang, Zhan Yuin Ong
-
Patent number: 8951962Abstract: Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.Type: GrantFiled: May 17, 2013Date of Patent: February 10, 2015Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Karthryn S. Prickett, Andrew A. Young
-
Patent number: 8951974Abstract: Provide are a peptide gel with practically sufficient mechanical strength and a self-assembling peptide capable of forming the peptide gel. The self-assembling peptide is formed of the following amino acid sequence: a1b1c1b2a2b3 db4a3b5c2b6a4 where: a1 to a4 each represent a basic amino acid residue; b1 to b6 each represent an uncharged polar amino acid residue and/or a hydrophobic amino acid residue, provided that at least five thereof each represent a hydrophobic amino acid residue; c1 and c2 each represent an acidic amino acid residue; and d represents a hydrophobic amino acid residue.Type: GrantFiled: March 26, 2014Date of Patent: February 10, 2015Assignees: Menicon Co., Ltd., National University Corporation Okayama UniversityInventors: Yusuke Nagai, Hidenori Yokoi, Koji Uesugi, Keiji Naruse
-
Patent number: 8933012Abstract: The present invention provides a novel glycopeptide antibiotic derivative.Type: GrantFiled: May 25, 2007Date of Patent: January 13, 2015Assignee: Shionogi & Co., Ltd.Inventors: Yasuhiro Nishitani, Osamu Yoshida, Tsutomu Iwaki, Issei Kato
-
Patent number: 8927488Abstract: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activity in vivo.Type: GrantFiled: May 17, 2011Date of Patent: January 6, 2015Assignee: Cebix, Inc.Inventors: Sheri Barrack, James Callaway, Michelle Mazzoni
-
Patent number: 8859490Abstract: Disclosed is a peptide nucleic acid monomer as well as a corresponding peptide nucleic acid molecule. The monomer comprises a terminal amino group and a terminal group A. The terminal amino group and the terminal group A are connected by an aliphatic moiety. The main chain of this aliphatic moiety is free of groups that are charged under physiological conditions. The terminal group A is one of —COOH, —COOR3, —COX, —COSR3, —CN, —CONH2, —CONHR3, —CONR3, R4, with R3 and R4 being H or an aliphatic, alicyclic, aromatic, arylaliphatic or arylalicyclic group, and X being a halogen atom. The terminal amino group is substituted by an aliphatic group with a main chain of at least two carbon atoms and optionally 0 to about 2 heteroatoms selected from the group N, O, S, Se and Si. The main chain has a polar head group Z.Type: GrantFiled: September 3, 2008Date of Patent: October 14, 2014Assignee: Nanyang Technological UniversityInventors: Chuan Fa Liu, Yun Zeng, Xiao Wei Lu
-
Patent number: 8828928Abstract: The inventions provided herein relate to amphiphilic peptides and particles comprising the amphiphilic peptides. Such amphiphilic peptides and particles described herein can be used as a delivery system, e.g., for therapeutic or diagnostic purposes, or as cell penetration vehicles or cell transfection agents.Type: GrantFiled: August 23, 2012Date of Patent: September 9, 2014Assignee: President and Fellows of Harvard CollegeInventors: Christian Dittrich, Gaudenz Danuser
-
Patent number: 8778874Abstract: Novel glycopeptide antibiotic derivatives. These derivatives are represented by the formula (aglycon part of glycopeptide antibiotic derivative)-(Sac-NH)—RA [wherein (aglycon part of glycopeptide antibiotic derivative) is the part formed by removing the sugar part from a known glycopeptide antibiotic derivative; (Sac-NH) part is an amino sugar part or a sugar chain part containing an amino sugar; and RA represents, e.g., the formula —X1—Ar1—X2—Y—X3—Ar2 (wherein X1, X2, and X3 each represents 1) a single bond or 2) a heteroatom or heteroatom-containing group selected from the group consisting of —N?, ?N—, —NR1—, —O—, etc.; Y represents —NR2CO— or —CONR2— (wherein R2 represents hydrogen or lower alkyl), etc.)]. These derivatives have antibacterial activity against vancomycin-resistant bacteria.Type: GrantFiled: November 24, 2005Date of Patent: July 15, 2014Assignees: National University Corporation Nagoya University, Shionogi & Co., Ltd.Inventors: Hirokazu Arimoto, Jun Lu, Yoshinori Yamano, Tatsuro Yasukata, Osamu Yoshida, Tsutomu Iwaki, Yutaka Yoshida, Issei Kato, Kenji Morimoto, Kayo Yasoshima
-
Patent number: 8772228Abstract: The present invention relates to nanofibers. In particular, the present invention provides aligned nanofiber bundle assemblies. In some embodiments, the aligned nanofiber bundle assemblies are used for tissue regeneration, controlled growth of cells, and related methods (e.g., diagnostic methods, research methods, drug screening).Type: GrantFiled: February 14, 2008Date of Patent: July 8, 2014Assignee: Northwestern UniversityInventors: Samuel I. Stupp, Shuming Zhang, Alvaro Mata, Megan A Greenfield
-
Publication number: 20140170124Abstract: The present disclosure provides a modified cecropin protein comprising a cecropin or a variant thereof fused to a hydrophilic tail lacking a C-terminal glycine. The present disclosure also provides pharmaceutical compositions, methods and uses of the modified cecropin protein or nucleic acid for treating or preventing endoparasites, such as Plasmodium, and bacteria.Type: ApplicationFiled: July 13, 2012Publication date: June 19, 2014Applicant: SOLARVEST BIOENERGY INC.Inventors: Subrata Chowdhury, Michael Thomas Horne
-
Patent number: 8729032Abstract: Provide are a peptide gel with practically sufficient mechanical strength and a self-assembling peptide capable of forming the peptide gel. The self-assembling peptide is formed of the following amino acid sequence: a1b1c1b2a2b3db4a3b5c2b6a4 where: a1 to a4 each represent a basic amino acid residue; b1 to b6 each represent an uncharged polar amino acid residue and/or a hydrophobic amino acid residue, provided that at least five thereof each represent a hydrophobic amino acid residue; c1 and c2 each represent an acidic amino acid residue; and d represents a hydrophobic amino acid residue.Type: GrantFiled: February 12, 2010Date of Patent: May 20, 2014Assignees: Menicon Co., Ltd., National University Corporation Okayama UniversityInventors: Yusuke Nagai, Hidenori Yokoi, Koji Uesugi, Keiji Naruse
-
Patent number: 8710187Abstract: The present invention relates to binding proteins specific for Vascular Endothelial Growth Factor A (VEGF-A), in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx (wherein xxx denotes the amino acid length of the VEGF-A mature protein) binding to Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2). Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: GrantFiled: April 29, 2011Date of Patent: April 29, 2014Assignee: Molecular Partners AGInventors: Hans Kaspar Binz, Patrik Forrer, Michael Tobias Stumpp
-
Patent number: 8697048Abstract: The present invention relates to the use of self-assembling peptide amphiphiles to prevent tumor formation by transplanted stem cells. The present invention further relates to the use of self-assembling peptide amphiphiles to treat cancers.Type: GrantFiled: December 21, 2011Date of Patent: April 15, 2014Assignee: Northwestern UniversityInventors: Li-Ru Zhao, John A. Kessler
-
Patent number: 8691755Abstract: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activity in vivo.Type: GrantFiled: May 4, 2012Date of Patent: April 8, 2014Assignee: Cebix ABInventors: Sheri Barrack, James Callaway, Michelle Mazzoni
-
Patent number: 8691205Abstract: Provided are methods of producing a mixture of mono- and di-pegylated IL-10.Type: GrantFiled: December 15, 2009Date of Patent: April 8, 2014Assignee: Merck Sharp & Dohme CorporationInventors: Steven J. Blaisdell, Collette M. Cutler, Brittany C. Paporello, Alexandre Ambrogelly
-
Patent number: 8617531Abstract: Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-? conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-?, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.Type: GrantFiled: December 14, 2007Date of Patent: December 31, 2013Assignee: Bolder Biotechnology, Inc.Inventors: George N. Cox, Mary S. Rosendahl
-
Patent number: 8586710Abstract: The present invention relates to a process for improving pegylation reaction yield of r-metHuG-CSF comprising conjugating r-metHuG-CSF to a PEG aldehyde at a free amine moiety at the N terminal end on the G-CSF in presence of a reducing agent in a pegylation buffer solution comprising a polyol having the formula CnH2n+2On where n is from 3 to 6, or a carbohydrate, or a derivative thereof wherein the concentration of said polyol or carbohydrate or derivative thereof is in the range of 0.1% to 10% w/w.Type: GrantFiled: May 4, 2009Date of Patent: November 19, 2013Assignee: USV, Ltd.Inventors: Nikhil Umesh Mohe, Dinesh Kumar Paliwal, Divya Lal Saksena, Chandrakesan Muralidharan, Rakesh Shekhawat, Sagar Satyanarayan Zawar
-
Patent number: 8455434Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.Type: GrantFiled: June 15, 2011Date of Patent: June 4, 2013Assignee: Bolder Biotechnology, Inc.Inventor: George N. Cox
-
Patent number: 8450459Abstract: The invention provides derivatives of IL-21 or variants thereof, methods of producing such variants, new variants of IL-21, and various methods of using such molecules.Type: GrantFiled: August 12, 2008Date of Patent: May 28, 2013Assignee: Novo Nordisk A/SInventors: Bernd Peschke, Christine Bruun Schiødt, Helle Wöldike, Florencio Zaragoza Dörwald, Anne Worsaae
-
Patent number: 8450284Abstract: The invention relates to lipopeptide building blocks consisting of a peptide chain comprising a coiled-coil domain, linked covalently to a lipid moiety comprising long alkyl or alkenyl chains, and optionally linked to an antigen; and to helical lipopeptide bundles and synthetic virus-like particles formed by aggregation. The nanometer size and shape of these bundles and particles, their stability under aqueous physiological conditions, their chemical composition, the possibility to incorporate B- and T-cell epitopes, and their production by chemical synthesis, make them highly suitable as vaccine delivery vehicles.Type: GrantFiled: December 6, 2007Date of Patent: May 28, 2013Assignee: Universitaet ZuerichInventors: Francesca Boato, Anabelle Freund, Arin Ghasparian, Kerstin Möhle, John A. Robinson, Richard M. Thomas
-
Publication number: 20130059775Abstract: The present invention relates to complexes of transcription factor decoys, their delivery to bacteria and their formulation. In particular, the present invention resides in an antibacterial complex comprising a nucleic acid sequence and one or more delivery moieties selected from quaternary amine compounds; bis-aminoalkanes and unsaturated derivatives thereof, wherein the amino component of the aminoalkane is an amino group forming part of a heterocyclic ring; and an antibacterial peptide.Type: ApplicationFiled: February 11, 2011Publication date: March 7, 2013Inventor: Michael McArthur
-
Patent number: 8383365Abstract: Modified FGF-21 polypeptides and uses thereof are provided.Type: GrantFiled: March 18, 2011Date of Patent: February 26, 2013Assignee: AMBRX, Inc.Inventors: Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, William M. Keefe, Nick Knudsen, Lillian Skidmore (Nee Ho), Jason Pinkstaff, Vadim Kraynov
-
Patent number: 8329645Abstract: The present invention relates to a polymyxin derivative wherein R1, R2 and R3 are optional and R1, R2, R3, R5, R8 and R9 are cationic or neutral amino acid residues selected so that the total number of positive charges at physiological pH is at least two but no more than three; and to a combination product comprising at least two such derivatives.Type: GrantFiled: February 5, 2009Date of Patent: December 11, 2012Assignee: Northern Antibiotics Ltd.Inventors: Martti Sakari Vaara, Timo Ilmari Vaara
-
Patent number: 8313739Abstract: Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics.Type: GrantFiled: March 7, 2011Date of Patent: November 20, 2012Assignee: ZymoGenetics, Inc.Inventor: Paul O. Sheppard
-
Patent number: 8309514Abstract: Disclosed herein are transmembrane transporter compounds containing guanidinium groups to enhance transport across biomembranes. Therapeutic and other biologically active moieties may be attached to the compounds. The transmembrane transporter compounds may include peptide nucleic acid monomer units.Type: GrantFiled: March 4, 2010Date of Patent: November 13, 2012Assignee: Nitto Denko CorporationInventors: Gang Zhao, Chieko Kitaura, Jian Liu, Lei Yu
-
Patent number: 8299032Abstract: A self-assembling peptide containing a polar amino acid residue and a nonpolar amino acid residue, wherein the self-assembling peptide contains an acidic amino acid residue and a basic amino acid residue as the polar amino acid residues, a total sum of charge of the acidic amino acid residue and charge of the basic amino acid residue in a neutral region is the number excluding 0, and the self-assembling peptide is capable of forming a beta (?)-sheet structure in which only the nonpolar amino acid residue is arranged on one face upon self-assembly in an aqueous solution.Type: GrantFiled: June 26, 2006Date of Patent: October 30, 2012Assignee: Menicon Co., Ltd.Inventors: Hidenori Yokoi, Takatoshi Kinoshita
-
Patent number: 8293708Abstract: Pharmaceutical compositions comprising pegylated growth hormone at pH 7 or below are provided.Type: GrantFiled: August 30, 2006Date of Patent: October 23, 2012Assignee: Novo Nordisk Health Care A/GInventor: Mats Reslow
-
Patent number: 8277817Abstract: The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a target agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two target agents and one PEG moiety. In alternative embodiments, the target agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one target agent. In more preferred embodiments, the target agent may comprise any peptide or protein of physiologic or therapeutic activity. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.Type: GrantFiled: June 1, 2011Date of Patent: October 2, 2012Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Publication number: 20120122769Abstract: Antibacterial antisense compounds and methods of their use in treating a Mycobacterium tuberculosis infection in a mammalian host are disclosed. The compounds include an antisense oligonucleotide conjugated to a carrier peptide that significantly enhances the antibacterial activity of the oligonucleotide. The antisense oligonucleotides contain 10-20 nucleotide bases and have a targeting nucleic acid sequence complementary to a target sequence containing or within 20 bases, in a downstream direction, of the translational start codon of a bacterial mRNA that encodes a bacterial protein essential for bacterial replication, where the compound binds to a target mRNA with a Tm of between 45° to 60° C. The carrier peptide is an arginine-rich peptide containing between 6 and 14 amino acids.Type: ApplicationFiled: November 10, 2011Publication date: May 17, 2012Applicant: AVI BIOPHARMA, INC.Inventor: Patrick L. Iversen
-
Patent number: 8178108Abstract: The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH comprising non-naturally encoded amino acids and hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.Type: GrantFiled: October 17, 2007Date of Patent: May 15, 2012Assignee: Ambrx, Inc.Inventors: Ying Buechler, Ricky Lieu, Michael Ong, Stuart Bussell, Nick Knudsen, Ho Sung Cho
-
Publication number: 20120115774Abstract: In some aspects, the present invention provides ultrashort lipopeptides which feature ?-amino acids or ?-peptides and demonstrate antimicrobial activity. Accordingly, some aspects of the present invention provide lipopeptide compositions and methods of making and using the compositions as antimicrobial agents.Type: ApplicationFiled: February 23, 2010Publication date: May 10, 2012Applicant: UNIVERSITY OF MANITOBAInventors: George Zhanel, Frank Schweizer
-
Patent number: 8158129Abstract: The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two therapeutic agents and one PEG moiety. In alternative embodiments, the therapeutic agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one therapeutic agent. In more preferred embodiments, the therapeutic agent may comprise any peptide or protein of physiologic or therapeutic activity, preferably a cytokine, more preferably interferon-?2b. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.Type: GrantFiled: July 7, 2011Date of Patent: April 17, 2012Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Patent number: 8124583Abstract: The present invention is directed to a composition useful for making homogeneously mineralized self assembled peptide-amphiphile nanofibers and nanofiber gels. The composition is generally a solution comprised of a positively or negatively charged peptide-amphiphile and a like signed ion from the mineral. Mixing this solution with a second solution containing a dissolved counter-ion of the mineral and/or a second oppositely charged peptide amphiphile, results in the rapid self assembly of the peptide-amphiphiles into a nanofiber gel and templated mineralization of the ions. Templated mineralization of the initially dissolved mineral cations and anions in the mixture occurs with preferential orientation of the mineral crystals along the fiber surfaces within the nanofiber gel. One advantage of the present invention is that it results in homogenous growth of the mineral throughout the nanofiber gel.Type: GrantFiled: June 22, 2009Date of Patent: February 28, 2012Assignee: Northwestern UniversityInventors: Samuel I. Stupp, Elia Beniash, Jeffrey D. Hartgerink
-
Patent number: 8114834Abstract: The present invention provides for self-assembling peptide amphiphiles that are capable of forming nanofibers. In particular, the present invention provides for diacetylene peptide amphiphiles that find use as scaffolds for tissue growth or for drug delivery.Type: GrantFiled: November 8, 2007Date of Patent: February 14, 2012Assignee: Northwestern UniversityInventors: Lorraine Hsu, Samuel I. Stupp
-
Patent number: 8114835Abstract: The present invention provides for compositions and methods for creating self-assembled peptide amphiphile (PA) structures. In particular, the present invention provides for two and three-dimensional structures of crosslinked PA microtexture structures useful for tissue engineering and drug discovery.Type: GrantFiled: November 8, 2007Date of Patent: February 14, 2012Assignee: Northwestern UniversityInventors: Alvaro Mata, Samuel I. Stupp
-
Patent number: 8097586Abstract: Novel exendins with modifications at one or more of following positions: 2, 14, 27 or 28 and polyethylene glycol derivatives thereof are provided. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.Type: GrantFiled: January 10, 2006Date of Patent: January 17, 2012Assignee: Wuxi Grandchamp Pharmaceutical Technology Co., Ltd.Inventors: Aifeng Lv, Changan Sun, Yali Wang
-
Patent number: 8080254Abstract: The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.Type: GrantFiled: September 22, 2006Date of Patent: December 20, 2011Assignee: Amgen, Inc.Inventors: Michael B. Mann, Randy Ira Hecht, Mary Ann Pellymounter, Christopher Francis Toombs
-
Patent number: 8063016Abstract: This invention provides methods of treatment using retro-inverso peptides derived from interleukin-6 (IL-6) having between 15 and about 40 amino acids, and including the sequence that is retro-inverso with respect to SEQ ID NO: 1, i.e. wherein said peptide comprises the sequence D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D-Ala-D-Leu-D-Ala-D-Glu. The peptides of the invention have the same activity as native IL-6 and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage.Type: GrantFiled: March 31, 2010Date of Patent: November 22, 2011Assignee: Myelos CorporationInventors: David E. Wright, D. Elliot Parks
-
Patent number: 7994124Abstract: The present invention relates to therapeutic methods for a protecting an animal from a disease or condition that can be treated by granulocyte colony-stimulating factor (G-CSF) wherein a composition comprising a cysteine variant of G-CSF is provided. Also disclosed herein are preferred cysteine variants of G-CSF for use in the composition.Type: GrantFiled: November 2, 2009Date of Patent: August 9, 2011Assignee: Bolder Biotechnology, Inc.Inventor: George N. Cox
-
Patent number: 7943128Abstract: There is provided an anti-microbial composition comprising a cationic peptide and a glycineglycine endopeptidase. The composition has been found to be synergistic against bacteria, especially Gram positive bacteria such as Staphylococcus aureus MSSA or MRSA. In one embodiment the composition comprises ranalexin, dermaseptin, magainin or mixtures thereof together with lysostaphin. The composition is useful for treating surfaces, including a wound surface in a patient or surfaces of an object (e.g. surgical instrument) or room.Type: GrantFiled: March 29, 2007Date of Patent: May 17, 2011Assignee: The University Court of the University of St AndrewsInventors: Peter John Coote, Shirley Graham
-
Publication number: 20110104263Abstract: The disclosure provides methods and compositions useful for treating claudin-4 associated disorders including cell proliferative disorders. The disclosure also provide claudin-family binding peptides useful in the methods of the disclosure.Type: ApplicationFiled: April 30, 2009Publication date: May 5, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: David D. Lo, Jun Ling, Mary M. Hamer, Thejani Rajapaksa
-
Publication number: 20110085989Abstract: This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.Type: ApplicationFiled: March 24, 2010Publication date: April 14, 2011Inventors: Jian He, Randal H. Eckert, Fengxia Qi, Maxwell H. Anderson, Wenyuan Shi
-
Publication number: 20110020216Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated therein or thereon, or diffusing from the scaffold composition such that the scaffold composition and/or a bioactive composition captures and eliminates undesirable cells from the body a mammalian subject. The devices mediate active recruitment, sequestration, and removal or elimination of undesirable cells from their host.Type: ApplicationFiled: June 11, 2008Publication date: January 27, 2011Inventors: David James Mooney, Omar abdel-Rahman Ali
-
Patent number: 7858581Abstract: Combinatorially generated peptides are provided that have binding affinity for polymethylmethacrylate (PMMA). The peptides may be used to deliver benefit agents to various PMMA surfaces.Type: GrantFiled: December 1, 2006Date of Patent: December 28, 2010Assignee: E. I. du Pont de Nemours and CompanyInventors: Scott D. Cunningham, David J. Lowe, John P. O'Brien, Hong Wang, Antoinette E. Wilkins